<DOC>
	<DOCNO>NCT00929864</DOCNO>
	<brief_summary>The purpose study demonstrate subcutaneous abatacept non-inferior ( bad ) subcutaneous adalimumab treatment subject rheumatoid arthritis biologic naive</brief_summary>
	<brief_title>Abatacept Versus Adalimumab Head-to-Head</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate severe Rheumatoid arthritis ( RA ) accord American College Rheumatology ( ACR ) criteria Methotrexate failure Naive RA biologics ≤5 year duration disease Disease Activity Score28 Creactive protein ( DAS28 CRP ) ≥ 3.2 Willingness selfinject subcutaneous ( SC ) drug Previous current medical condition warning use tumor necrosis factor ( TNF ) block agent History active chronic hepatitis Cancer last 5 year History severe chronic recurrent bacterial viral infection Risk tuberculosis Current symptom severe , progressive , uncontrolled renal , hepatic , hematologic , Gastrointestinal , pulmonary , cardiac , neurologic , cerebral disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>